SaleApr 28, 2026, 07:37 AM
RCKT Sells Priority Review Voucher for $180M; Extends Cash Runway
AI Summary
Rocket Pharmaceuticals, Inc. announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in cash. This non-dilutive capital infusion is expected to extend the company's cash runway into the second quarter of 2028. The proceeds will be used to advance Rocket's prioritized cardiovascular gene therapy pipeline, including programs for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
Key Highlights
- Rocket Pharmaceuticals entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV).
- The company will receive $180 million in cash upon the closing of the sale.
- The PRV was granted following FDA approval of KRESLADI™ (marnetegragene autotemcel).
- The monetization provides $180 million in non-dilutive capital.
- This transaction extends Rocket's cash runway into the second quarter of 2028.
- Proceeds will support the advancement of cardiovascular gene therapy programs.